Key Takeaways & Executive Findings
- •• Stem cell-derived EVs demonstrate significant therapeutic potential in preclinical and clinical settings, particularly for tissue repair and immune modulation. • Standardization of EV isolation, characterization, and production is critical for clinical translation and regulatory approval. • Engineering strategies, such as surface modification and cargo loading, enhance EV targeting and therapeutic efficacy. • EVs offer a safer alternative to whole-cell therapies, reducing risks of immunogenicity and tumorigenicity.
Abstract
Stem cell-derived extracellular vesicles (EVs) have emerged as promising therapeutic agents due to their ability to modulate immune responses, promote tissue regeneration, and deliver bioactive molecules. This review summarizes the current state of clinical trials investigating EVs in various diseases, including cardiovascular, neurological, and orthopedic conditions. We discuss the challenges in standardization, scalability, and quality control, and highlight recent advances in engineering EVs for enhanced targeting and efficacy. The translational potential of EVs is underscored by their safety profile and versatility, positioning them as a novel class of cell-free therapeutics. Future directions include the development of EV-based biomarkers and combination therapies to maximize clinical benefit.
1. Introduction
Stem cell-derived extracellular vesicles (EVs) have garnered considerable attention as cell-free therapeutic agents, offering a safer and more versatile alternative to whole-cell transplantation. EVs are lipid bilayer-enclosed nanoparticles that mediate intercellular communication by transferring proteins, lipids, and nucleic acids. Their intrinsic properties, including low immunogenicity, biocompatibility, and ability to cross biological barriers, make them attractive for treating a wide range of diseases.
Clinical trials have begun to evaluate the safety and efficacy of EV-based therapies in conditions such as myocardial infarction, stroke, and osteoarthritis. However, challenges remain in standardizing production, ensuring consistent quality, and scaling up manufacturing. This review provides a comprehensive overview of the current landscape of EV-based clinical trials, discusses the hurdles to clinical translation, and highlights emerging strategies to overcome these obstacles.
Loading authentic research manuscript (Pages 1–5)...
Y. Wang, X. Li, J. Zhang, et al. (2026). Stem Cell-Derived Extracellular Vesicles: Therapeutic Potential in Clinical Trials and Translational Medicine. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are stem cell-derived extracellular vesicles?
Stem cell-derived extracellular vesicles are small membrane-bound particles released by stem cells that carry proteins, lipids, and nucleic acids, mediating intercellular communication and therapeutic effects.
What diseases are being targeted in clinical trials with EVs?
Clinical trials are exploring EVs for cardiovascular diseases, neurological disorders, orthopedic injuries, and immune-related conditions, among others.
What are the main challenges in EV-based therapies?
Key challenges include standardization of isolation and characterization, scalability of production, quality control, and ensuring consistent therapeutic potency.
How can EVs be engineered for better therapeutic outcomes?
EVs can be engineered by surface modification to enhance targeting, loading with therapeutic cargo, or modifying their lipid composition to improve stability and uptake.
Are EV-based therapies safe?
EVs are generally considered safe due to their low immunogenicity and lack of tumorigenic potential, but ongoing clinical trials are essential to fully establish their safety profile.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.